Elexacaftor is a small molecule CFTR corrector utilized in combination therapy to treat cystic fibrosis in patients with the F508del-CFTR mutation. To ensure the safety and efficacy of this medication,… Read more









Elexacaftor is a small molecule CFTR corrector utilized in combination therapy to treat cystic fibrosis in patients with the F508del-CFTR mutation. To ensure the safety and efficacy of this medication, laboratories rely on high-quality reference standards, including Elexacaftor API, its related impurities, metabolites, and stable isotope-labelled compounds. These materials are essential for rigorous analytical testing, method validation, and quality control processes. By utilizing these standards, analytical chemists can accurately conduct impurity profiling, monitor degradation products resulting from processes like hydrolysis or oxidation, and perform precise quantification in complex matrices. Whether developing new analytical methods or conducting long-term stability studies, accessing reliable reference standards is critical for maintaining compliance with regulatory guidelines and ensuring the integrity of the therapeutic product throughout its lifecycle.